Table 4.
Effect of individualized therapy of ASMs on quality of life in the responders group and non-responders group (n = 100).
| QOL subscales | Responders group (n = 43) |
Non-responders group (n = 57) |
||||||
|---|---|---|---|---|---|---|---|---|
| Mono-therapy | Bi-therapy | Poly-therapy | p-value | Mono-therapy | Bi-therapy | Poly-therapy | p-value | |
| Seizure worry (mean ± SD) | 62.04 ± 3.19 | 58.43 ± 3.15 | 60.0 ± 3.05 | 0.006∗∗ | 53.26 ± 9.09 | 44.70 ± 7.81 | 44.4 ± 8.44 | 0.0044∗∗ |
| Overall quality of life (mean ± SD) | 56.09 ± 4.58 | 55.14 ± 6.70 | 51.14 ± 4.48 | 0.1156 | 42.93 ± 6.88 | 39.62 ± 6.38 | 35.46 ± 8.81 | 0.0231∗ |
| Emotional wellbeing (mean ± SD) | 56.31 ± 4.28 | 53.07 ± 4.37 | 53.14 ± 3.89 | 0.0569 | 48.86 ± 9.81 | 45.51 ± 6.09 | 45.6 ± 5.87 | 0.3167 |
| Energy/fatigue (mean ± SD) | 59.90 ± 3.61 | 58.71 ± 2.81 | 57.71 ± 3.09 | 0.2655 | 52.26 ± 9.33 | 50.44 ± 7.21 | 47.66 ± 4.33 | 0.2231 |
| Cognitive function (mean ± SD) | 61.40 ± 4.81 | 59.78 ± 3.19 | 57.28 ± 3.72 | 0.0813 | 53.46 ± 10.45 | 49.25 ± 8.26 | 44.53 ± 11.74 | 0.0536∗ |
| Medication effects (mean ± SD) | 57.54 ± 3.88 | 58.21 ± 2.99 | 57.14 ± 3.76 | 0.7825 | 47.53 ± 3.94 | 46.33 ± 4.81 | 47.53 ± 5.86 | 0.6562 |
| Social functioning (mean ± SD) | 54.00 ± 3.58 | 52.78 ± 4.54 | 51.85 ± 3.76 | 0.4030 | 47.53 ± 9.09 | 42.18 ± 9.84 | 37.46 ± 9.17 | 0.0196∗ |
| overall weighted average health-related quality of life score (mean ± SD) | 58.1 ± 2.03 | 56.37 ± 1.74 | 54.92 ± 1.82 | 0.0009∗∗∗ | 49.71 ± 6.87 | 45.55 ± 4.86 | 42.39 ± 6.12 | 0.0042∗∗ |
Data are represented as (mean ± SD); ∗p < 0.05, ∗∗P < 0.005, ∗∗∗P < 0.0005.